Celsius’ CEL383 is a possible first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the remedy of inflammatory bowel illness (IBD)
NORTH CHICAGO, Sick., June 27, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) introduced immediately the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology firm pioneering new therapies for sufferers with inflammatory illness. Celsius’ lead investigational asset is CEL383, a possible first-in-class anti-TREM1 antibody that has accomplished a Section 1 scientific examine for the remedy of IBD.
TREM1 has been recognized as a key illness driver gene in IBD, the place it’s expressed on inflammatory monocytes and neutrophils. In these cell varieties and others, TREM1 is upstream of a number of identified inflammatory pathways and acts as an amplifier of irritation.
“Given the potential relevance of TREM1 as a key driver of irritation and pathology in IBD and different situations, we’re desperate to advance the event of CEL383 with a objective of serving to extra sufferers with IBD obtain remission,” mentioned Kori Wallace, M.D., Ph.D., vp, international head of immunology scientific improvement, AbbVie.
“AbbVie shares our pleasure in regards to the potential of TREM1 inhibition for sufferers with inflammatory illness,” mentioned Tariq Kassum, M.D., chief government officer, Celsius. “I would prefer to thank the Celsius crew for his or her relentless efforts within the discovery of CEL383. We look ahead to the additional improvement of this promising program, which we hope will supply a brand new method to the remedy of IBD.”
Underneath the phrases of the settlement, AbbVie has acquired all excellent Celsius fairness for $250 million in money, topic to sure customary changes.
About CEL383CEL383 is an investigational antibody directed in direction of TREM1. In preclinical assays, CEL383 has been proven to inhibit TREM1 signaling, lowering the degrees of a number of inflammatory mediators of excessive scientific relevance in inflammatory situations. A section 1 first-in-human, randomized, double-blind, placebo-controlled, single ascending dose examine evaluating the security, tolerability and pharmacokinetics of CEL383 in wholesome volunteers has concluded (NCT05901883).
AdvisorsAbbVie’s authorized advisor was Covington & Burling LLP. Celsius’ monetary advisor was Centerview Companions LLC and Goodwin Procter LLP served as authorized advisor.
About AbbVieAbbVie’s mission is to find and ship revolutionary medicines and options that remedy severe well being points immediately and tackle the medical challenges of tomorrow. We try to have a outstanding influence on individuals’s lives throughout a number of key therapeutic areas – immunology, oncology, neuroscience, and eye care – and services in our Allergan Aesthetics portfolio. For extra details about AbbVie, please go to us at www.abbvie.com. Observe @abbvie on LinkedIn, Fb, Instagram, X (previously Twitter), and YouTube.
About Celsius TherapeuticsCelsius Therapeutics is a clinical-stage biotechnology firm growing novel medicines in inflammatory illness. The corporate’s lead therapeutic candidate is an anti-TREM1 antibody for the remedy of IBD. Celsius is predicated in Cambridge, Mass. For extra info, please go to https://celsiustx.com, or comply with us on LinkedIn or X (previously Twitter).
Ahead-Wanting StatementsSome statements on this information launch are, or could also be thought of, forward-looking statements for functions of the Non-public Securities Litigation Reform Act of 1995. The phrases “imagine,” “count on,” “anticipate,” “mission” and related expressions and makes use of of future or conditional verbs, usually establish forward-looking statements. AbbVie cautions that these forward-looking statements are topic to dangers and uncertainties which will trigger precise outcomes to vary materially from these expressed or implied within the forward-looking statements. Such dangers and uncertainties embody, however should not restricted to, challenges to mental property, competitors from different merchandise, difficulties inherent within the analysis and improvement course of, opposed litigation or authorities motion, and adjustments to legal guidelines and rules relevant to our business. Further details about the financial, aggressive, governmental, technological and different elements which will have an effect on AbbVie’s operations is ready forth in Merchandise 1A, “Threat Components,” of AbbVie’s 2023 Annual Report on Kind 10-Okay, which has been filed with the Securities and Trade Fee, as up to date by its subsequent Quarterly Reviews on Kind 10-Q. Ahead wanting statements converse solely as of the date they’re made. Readers are cautioned to not put undue reliance on ahead wanting statements, and AbbVie undertakes no obligation, and particularly declines, to launch publicly any revisions to forward-looking statements on account of subsequent occasions or developments, besides as required by regulation.
SOURCE AbbVie